Phase 3
Completed N=12
Use of Vasopressin Following the Fontan Operation
pleural effusion · Single-ventricle
Source: ClinicalTrials.gov NCT02975999 ↗
Enrolled (actual)
12
Serious AEs
0.0%
Results posted
Oct 2024
Primary outcomePrimary: Chest Tube Drainage — 686.83; 535.50 ml/kg
◆ Published Evidence
No publication linked
No peer-reviewed publication reporting this trial's results has been linked yet. This can indicate results are unpublished — a known publication-bias signal. We re-check periodically.
Summary
The purpose of this pilot study is to prepare for a larger study to determine whether Vasopressin following the Fontan operation will decrease chest tube output and duration.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Chest Tube Drainage |
686.83; 535.50 | — |
| SECONDARY Length of Hospital Stay |
5; 4.5 | — |
Eligibility Criteria
Inclusion Criteria
- Subjects between 1.5-7 years old undergoing Fontan operation.
Exclusion Criteria
- Patients with a planned fenestrated Fontan.
- Patients undergoing revision surgery for failing Fontan.
- Evidence of renal insufficiency prior to surgery defined by creatinine >1 mg/dl.
- Planned arch reconstruction at the time of the Fontan procedure
Data sourced from ClinicalTrials.gov (NCT02975999). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.